Learn how one of the world’s top cancer research institutes, Gustave Roussy, has integrated Alira Health’s SpherePX technology into Project Interception to advance cancer prevention.
A flexible, modular solution, SpherePX streamlines the design, launch, and execution of post-market studies — delivering meaningful, real-time evidence grounded in patient experience.
Key Differentiators
Platform Benefits
Key Differentiators
Platform Benefits
Payers, regulators, and providers want compliance — and context.
What defines high-impact post-market studies:
Even with better platforms and regulatory openness, most post-market studies still fall short.
The opportunity isn’t more data — it’s the right data: connected, contextual, and patient-centered.
Ready in weeks, not months.
SpherePX adapts to your evidence strategy — supporting standalone, hybrid, or longitudinal designs across all phases of the product lifecycle.
Study Types Supported
In environments where patients live and care happens.
| Approachable Design | Flexible and Multi-Setting | Scalable and Submission-Ready |
|---|---|---|
| Mobile-first, multilingual, literacy-aware | Modular design fits study needs and geographies | Designed for rapid localization and high-volume enrollment |
| Seamless and intuitive onboarding | Works across clinic, home, long-term care, and virtual care | Aligned with global regulatory submission standards |
| Patient- and provider-facing tools | Dynamic workflow and content builder (CMS) | Supports access, medical affairs, and regulatory use |
Most platforms ask patients to adapt. SpherePX adapts to them.
Reduce complexity
Use intuitive tools that let teams focus on what matters most
Accelerate set-up and deployment
Launch quickly with a flexible, no-code platform — even mid-study
Scale with confidence
Grow across studies, sites, and geographies without disruption
Reduce administrative burden
Automate documentation and workflows so teams can focus on care
Streamline patient management
Automate documentation and workflows so teams can focus on care
Access real-time data
Monitor study performance and patient input as it’s captured
Personalized for every patient
Tailored to the needs of each study and population
Intuitive for all users
Designed for any level of digital experience or literacy
Empowering patients through insight
Supports informed decisions with built-in education modules
Transform how you capture, manage, and act on study data using AI you build to fit your workflows with our integrated AI Assistant Creator
Trusted across studies, geographies, and populations.
Built on real-world needs and real results.
Design and deploy a Virtual Site to compare a stool DNA test for colorectal cancer (CRC) to colonoscopy. This study was a prospective, cross-sectional, multi-center study and expected to enroll approximately 12,500 patients to ensure at least 60 pathologically confirmed CRC cases with a valid stool DNA test.
With the following objectives to:
Solution Scoping, Design and Development
Launch virtual arm of clinical trial
The primary objective of this registry is to compare the frequency of major congenital malformations (MCMs) among prospectively enrolled women with migraine exposed to the Sponsor’s drugs during pregnancy with 2 unexposed comparator groups: prospectively enrolled women with migraine (treated or untreated), and women without migraine.
A secondary objective of the study is to assess the treatment decision-making process of physicians, and their understanding of the patient experience.
Solution Scoping, Design and Development
The factors driving success include building on the success of past registries to rapidly implement study template, allowing for faster start-up and launch; patient compensation to drive engagement as we steadily recruit and onboard new patients; and with strong communication and sponsor support, driving mid study updates managed in due time and planned budget, following FDA regulations.
Evaluate the real-world effectiveness of adding the sponsor’s drug to standard SLE* care, focusing on clinical outcomes and skin manifestations. The project captures unique data on medication use through standardized assessments and patient diaries, enabling valuable insights for stakeholders.
Use a conversational app to make data collection more engaging and approachable, with an adaptive language tree that changes based on the user’s motivation and persona.
The factors driving success include a user-friendly application—reducing decision fatigue, promoting adherence, and delivered in multiple languages across nine countries; and strong partner support, dedicated to monitoring by leveraging our real-time dashboards.
Partnering with a hospital in France to develop personalized prevention in people at high risk of cancer. Cancer interception relies on a combination of early detection and prevention/ treatment to eradicate cancers before their clinical phase.
The objective of the program is to reduce the risk of stage 2 or higher (or equivalent) malignant tumors by 30% over 5 years in participants, by identifying people at increased risk of cancer as early as possible, and offering them a personalized course of screening and prevention of the disease.
Solution Scoping, Design and Development
The 2 main factors contributing to success are: 1) focusing on what was previously unable to be done effectively, i.e. follow up with the participant after the visit by providing them with a prevention plan and personalized follow-up and 2) dramatically reducing administrative burden on HCPs by providing a single unified platform, where previously multiple systems and paper documentation was being utilized.
SpherePX meets the highest standards for data protection, interoperability, and multi-market execution.
SpherePX is embedded within Alira Health’s evidence ecosystem — where strategy, science, and software work together.
Beyond the platform — you’re gaining a partner who understands the science, the strategy, and the people behind every study.